| Literature DB >> 30862721 |
Ran Tao1, Najiba Murad1, Zhenhua Xu1, Peng Zhang2, Konstantin Okonechnikov3,4, Marcel Kool3,4, Samuel Rivero-Hinojosa1, Christopher Lazarski1, Pan Zheng2, Yang Liu2, Charles G Eberhart5, Brian R Rood1, Roger Packer1, Yanxin Pei6.
Abstract
A subset of group 3 medulloblastoma frequently harbors amplification or overexpression of MYC lacking additional focal aberrations, yet it remains unclear whether MYC overexpression alone can induce tumorigenesis and which cells give rise to these tumors. Here, we showed that astrocyte progenitors in the early postnatal cerebellum were susceptible to transformation by MYC. The resulting tumors specifically resembled human group 3 medulloblastoma based on histology and gene-expression profiling. Gene-expression analysis of MYC-driven medulloblastoma cells revealed altered glucose metabolic pathways with marked overexpression of lactate dehydrogenase A (LDHA). LDHA abundance correlated positively with MYC expression and was associated with poor prognosis in human group 3 medulloblastoma. Inhibition of LDHA significantly reduced growth of both mouse and human MYC-driven tumors but had little effect on normal cerebellar cells or SHH-associated medulloblastoma. By generating a new mouse model, we demonstrated for the first time that astrocyte progenitors can be transformed by MYC and serve as the cells of origin for group 3 medulloblastoma. Moreover, we identified LDHA as a novel, specific therapeutic target for this devastating disease. SIGNIFICANCE: Insights from a new model identified LDHA as a novel target for group 3 medulloblastoma, paving the way for the development of effective therapies against this disease. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30862721 PMCID: PMC6467710 DOI: 10.1158/0008-5472.CAN-18-1787
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312